WEBULL

European Penny Stock Highlights: BioPorto And Two More To Watch

Simply Wall St · 2d ago

The pan-European STOXX Europe 600 Index remained largely stable, reflecting the broader market's cautious sentiment amid tech stock volatility and geopolitical tensions. For investors looking beyond established giants, penny stocks—often representing smaller or emerging companies—offer intriguing possibilities. Despite being a term from earlier market times, these stocks can still present growth opportunities when supported by robust financials.

Let's uncover some gems from our specialized screener.

BioPorto (CPSE:BIOPOR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: BioPorto A/S is an in-vitro diagnostics company that develops biomarker tests for early detection of kidney injury in critically ill patients across Denmark, Europe, North America, and Asia, with a market cap of DKK559.47 million.

Operations: The company's revenue is primarily generated from NGAL Tests (DKK28.22 million), followed by Antibodies (DKK10.54 million), ELISA Kits (DKK1.38 million), and Royalty and Other Revenue (DKK0.15 million).

Market Cap: DKK559.47M

BioPorto A/S, with a market cap of DKK559.47 million, is focused on developing biomarker tests and has recently announced plans for an expanded U.S. Adult Urine NGAL Validation Study. This initiative aligns with feedback from the FDA and aims to provide robust data for future submissions, though it will increase study costs by DKK20 million and delay cash flow positivity to late 2028. Despite being debt-free and having assets exceeding liabilities, BioPorto remains unprofitable with a volatile share price and limited cash runway under one year if free cash flow trends persist.

CPSE:BIOPOR Revenue & Expenses Breakdown as at Jul 2026
CPSE:BIOPOR Revenue & Expenses Breakdown as at Jul 2026

Nanoform Finland Oyj (HLSE:NANOFH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Nanoform Finland Oyj provides nanotechnology and drug particle engineering services to the pharma and biotech industries in Europe and the United States, with a market cap of €69.56 million.

Operations: The company generates €5.42 million in revenue from providing nanoforming, formulation, and analytical services.

Market Cap: €69.56M

Nanoform Finland Oyj, with a market cap of €69.56 million, is gaining traction in the nanotechnology sector through strategic agreements and presentations at major conventions. Recent earnings indicate revenue growth to €1.27 million for Q1 2026, although the company remains unprofitable with a net loss of €3.43 million. An exclusivity agreement with a U.S.-based biopharmaceutical firm highlights potential future revenue streams through milestone payments and royalties, contingent on successful project progression. Nanoform's robust cash position exceeds its liabilities and supports operations for over three years despite ongoing losses and high share price volatility.

HLSE:NANOFH Financial Position Analysis as at Jul 2026
HLSE:NANOFH Financial Position Analysis as at Jul 2026

Raisio (HLSE:RAIVV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Raisio plc, with a market cap of €414.75 million, produces and sells food and food ingredients in Finland, the United Kingdom, and internationally through its subsidiaries.

Operations: The company's revenue is primarily generated from its Brands and Industrial segment, which accounts for €220.6 million.

Market Cap: €414.75M

Raisio plc, with a market cap of €414.75 million, has demonstrated financial stability and strategic growth initiatives. The company reported Q1 2026 sales of €57.5 million and net income of €6.5 million, showing improved profit margins from the previous year. Raisio is debt-free, which enhances its financial flexibility but its dividend yield of 5.74% isn't well covered by earnings or cash flows. Recent investments in the Nokia Mill have bolstered production capabilities for gluten-free oats and expanded international markets in Spain and the Netherlands, aligning with Raisio's strategy for growth in breakfast products.

HLSE:RAIVV Revenue & Expenses Breakdown as at Jul 2026
HLSE:RAIVV Revenue & Expenses Breakdown as at Jul 2026

Summing It All Up

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.